Trial Type: Skin

LS-P-MAST
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Almhanna, Khaldoun
LS-P-DANCE
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
Protocol Status: OPEN TO ACCRUAL
Trial Type: Skin
Contact: Constantinou, Maria
LS-P-IGNYTE-3
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician’s Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
Protocol Status: OPEN TO ACCRUAL
Trial Type: Skin
Contact: Constantinou, Maria
SWOGS2205
Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Protocol Status: OPEN TO ACCRUAL
Contact: Graff, Stephanie
BH-P-FLOAT
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito
ALTE2131
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
Protocol Status: OPEN TO ACCRUAL
Contact: DeNardo, Bradley
BH-P-EARTH
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies
Protocol Status: OPEN TO ACCRUAL
Contact: Hadfield, Matthew